A detailed history of Geode Capital Management, LLC transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 378,058 shares of ELDN stock, worth $1.64 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
378,058
Previous 344,489 9.74%
Holding current value
$1.64 Million
Previous $909,000 3.52%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.41 - $3.19 $80,901 - $107,085
33,569 Added 9.74%
378,058 $941,000
Q2 2024

Aug 09, 2024

BUY
$1.57 - $3.12 $256,833 - $510,394
163,588 Added 90.43%
344,489 $909,000
Q1 2024

May 13, 2024

BUY
$1.54 - $2.13 $7,487 - $10,356
4,862 Added 2.76%
180,901 $372,000
Q3 2023

Nov 13, 2023

BUY
$1.14 - $1.66 $7,283 - $10,605
6,389 Added 3.77%
176,039 $241,000
Q2 2023

Aug 11, 2023

BUY
$1.34 - $2.85 $54,268 - $115,422
40,499 Added 31.36%
169,650 $232,000
Q4 2022

Feb 13, 2023

SELL
$2.17 - $2.75 $681 - $863
-314 Reduced 0.24%
129,151 $299,000
Q3 2022

Nov 14, 2022

BUY
$2.45 - $3.88 $1,663 - $2,634
679 Added 0.53%
129,465 $357,000
Q2 2022

Aug 12, 2022

BUY
$2.34 - $3.96 $4,857 - $8,220
2,076 Added 1.64%
128,786 $314,000
Q4 2021

Feb 11, 2022

SELL
$4.02 - $6.07 $3,408 - $5,147
-848 Reduced 0.66%
126,710 $558,000
Q3 2021

Nov 12, 2021

BUY
$5.94 - $8.46 $17,487 - $24,906
2,944 Added 2.36%
127,558 $788,000
Q2 2021

Aug 13, 2021

BUY
$7.62 - $11.75 $194,241 - $299,519
25,491 Added 25.72%
124,614 $985,000
Q1 2021

May 12, 2021

BUY
$9.85 - $19.22 $976,361 - $1.91 Million
99,123 New
99,123 $1.06 Million

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $59.8M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.